Other · developed by Innate Pharma
NNC 0141-0000-0100 (NNC 0141) is a drug given subcutaneously or intravenously in single and multiple-dose study cohorts. It is studied in inflammation and rheumatoid arthritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01370902 | Phase 1 | Inflammation | Completed | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
InflammationRheumatoid Arthritis
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →